fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Linezolid

Form:

7 of 7 products shown

3 Limited Use · 4 not a benefit

Apo-Linezolid · DIN 02426552 · 600 mg · tablet

Limited Use, Reason for Use code 362, 363, 364 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 362, 363, 364 required
Write on scriptone applicable Reason for Use code, 362 or 363 or 364 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 362, 363, 364
Coverage limit: For the treatment of patients with: Reason for Use code 362 Methicillin-resistant Staphylococcus species (MRSA, MRSE) infections* in patients who are intolerant or have failed vancomycin therapy, or have contraindications to venous access. Coverage limit: LU Authorization Period: 1 year Reason for Use code 363 Vancomycin resistant Enterococcus species (VRE) infections* in patients switching from IV linezolid. Coverage limit: LU Authorization Period: 1 year Reason for Use code 364 Step-down therapy for the treatment of methicillin-resistant Staphylococcus species or vancomycin resistant Enterococcus species (VRE) infections* after parenteral therapy or hospital/ emergency department discharge. Coverage limit: * Infections must be documented and culture proven. Not approved for colonization (e.g. nares, urine, etc). Maximum 28 days supply. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Apo-Linezolid · DIN 02426552 Manufacturer: Apotex Inc.; listing date 2014-10-29 Health Canada: Marketed since 2019-10-31 · brand APO-LINEZOLID · ATC J01XX08 LINEZOLID · form Tablet · route Oral · ingredients LINEZOLID 600 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Linezolid: Formulary list price $19.30 per unit (the source does not state the unit; exact figure $19.3041). What the ministry pays, not the patient.

Ministry pays: $19.3041 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02426552)

Source record
DIN 02426552: Apo-Linezolid Raw flags: sec12=Y, sec3=Y Item: 084000054; group id 136; item number 0229; lccId 00014; manufacturer id APX Source form: Tab; strength: 600mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $19.3041; ministry $19.3041 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02426552 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91113
Interchangeable products
Jamp Linezolid · DIN 02520354 · $19.3041 Sandoz Linezolid · DIN 02422689 · $19.3041 Zyvoxam · DIN 02243684 · not recorded
Shortage status: resolved shortage (ended November 3, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02426552
Shortage record checked October 6, 2026

Jamp Linezolid · DIN 02520354 · 600 mg · tablet

Limited Use, Reason for Use code 362, 363, 364 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 362, 363, 364 required
Write on scriptone applicable Reason for Use code, 362 or 363 or 364 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 362, 363, 364
Coverage limit: For the treatment of patients with: Reason for Use code 362 Methicillin-resistant Staphylococcus species (MRSA, MRSE) infections* in patients who are intolerant or have failed vancomycin therapy, or have contraindications to venous access. Coverage limit: LU Authorization Period: 1 year Reason for Use code 363 Vancomycin resistant Enterococcus species (VRE) infections* in patients switching from IV linezolid. Coverage limit: LU Authorization Period: 1 year Reason for Use code 364 Step-down therapy for the treatment of methicillin-resistant Staphylococcus species or vancomycin resistant Enterococcus species (VRE) infections* after parenteral therapy or hospital/ emergency department discharge. Coverage limit: * Infections must be documented and culture proven. Not approved for colonization (e.g. nares, urine, etc). Maximum 28 days supply. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Jamp Linezolid · DIN 02520354 Manufacturer: Jamp Pharma Corporation; listing date 2023-01-31 Health Canada: Marketed since 2022-10-31 · brand JAMP LINEZOLID · ATC J01XX08 LINEZOLID · form Tablet · route Oral · ingredients LINEZOLID 600 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Linezolid: Formulary list price $19.30 per unit (the source does not state the unit; exact figure $19.3041). What the ministry pays, not the patient.

Ministry pays: $19.3041 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02520354)

Source record
DIN 02520354: Jamp Linezolid Raw flags: sec12=Y, sec3=Y Item: 084000054; group id 136; item number 0229; lccId 00014; manufacturer id JPC Source form: Tab; strength: 600mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $19.3041; ministry $19.3041 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02520354 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100955
Interchangeable products
Apo-Linezolid · DIN 02426552 · $19.3041 Sandoz Linezolid · DIN 02422689 · $19.3041 Zyvoxam · DIN 02243684 · not recorded
Shortage status: resolved shortage (ended August 1, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02520354
Shortage record checked October 6, 2026

Sandoz Linezolid · DIN 02422689 · 600 mg · tablet

Limited Use, Reason for Use code 362, 363, 364 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 362, 363, 364 required
Write on scriptone applicable Reason for Use code, 362 or 363 or 364 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 362, 363, 364
Coverage limit: For the treatment of patients with: Reason for Use code 362 Methicillin-resistant Staphylococcus species (MRSA, MRSE) infections* in patients who are intolerant or have failed vancomycin therapy, or have contraindications to venous access. Coverage limit: LU Authorization Period: 1 year Reason for Use code 363 Vancomycin resistant Enterococcus species (VRE) infections* in patients switching from IV linezolid. Coverage limit: LU Authorization Period: 1 year Reason for Use code 364 Step-down therapy for the treatment of methicillin-resistant Staphylococcus species or vancomycin resistant Enterococcus species (VRE) infections* after parenteral therapy or hospital/ emergency department discharge. Coverage limit: * Infections must be documented and culture proven. Not approved for colonization (e.g. nares, urine, etc). Maximum 28 days supply. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Sandoz Linezolid · DIN 02422689 Manufacturer: Sandoz Canada Inc.; listing date 2014-10-29 Health Canada: Marketed since 2014-08-25 · brand SANDOZ LINEZOLID · ATC J01XX08 LINEZOLID · form Tablet · route Oral · ingredients LINEZOLID 600 MG · company Sandoz canada incorporated · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Sandoz Linezolid: Formulary list price $19.30 per unit (the source does not state the unit; exact figure $19.3041). What the ministry pays, not the patient.

Ministry pays: $19.3041 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02422689)

Source record
DIN 02422689: Sandoz Linezolid Raw flags: sec12=Y, sec3=Y Item: 084000054; group id 136; item number 0229; lccId 00014; manufacturer id SDZ Source form: Tab; strength: 600mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $19.3041; ministry $19.3041 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02422689 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90735
Interchangeable products
Apo-Linezolid · DIN 02426552 · $19.3041 Jamp Linezolid · DIN 02520354 · $19.3041 Zyvoxam · DIN 02243684 · not recorded
Shortage status: resolved shortage (ended November 7, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02422689
Shortage record checked October 6, 2026

Linezolid Injection · DIN 02481278 · 2 mg/mL · injection-300mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Linezolid Injection · DIN 02481278 Manufacturer: Jamp Pharma Corporation; listing date 2020-05-29 Health Canada: Marketed since 2019-12-30 · brand LINEZOLID INJECTION · ATC J01XX08 LINEZOLID · form Solution · route Intravenous · ingredients LINEZOLID 2 MG/ML · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Linezolid Injection: Formulary list price $88.74 per unit (the source does not state the unit; exact figure $88.7400). What the ministry pays, not the patient.

Ministry pays: $88.7400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02481278)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02481278). DIN 02481278: Linezolid Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 084000068; group id 135; item number 0228; lccId None; manufacturer id JPC Source form: Inj-300mL Pk; strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $88.7400; ministry $88.7400 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02481278 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97176
Interchangeable products
Linezolid Injection · DIN 02539748 · $88.7400 Zyvoxam · DIN 02243685 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481278
Shortage record checked October 6, 2026

Linezolid Injection · DIN 02539748 · 2 mg/mL · injection-300mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Linezolid Injection · DIN 02539748 Manufacturer: Eugia Pharma Inc.; listing date 2026-09-29 Health Canada: Marketed since 2026-06-16 · brand LINEZOLID INJECTION · ATC J01XX08 LINEZOLID · form Solution · route Intravenous · ingredients LINEZOLID 2 MG/ML · company Eugia pharma inc. · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Linezolid Injection: Formulary list price $88.74 per unit (the source does not state the unit; exact figure $88.7400). What the ministry pays, not the patient.

Ministry pays: $88.7400 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02539748)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02539748). DIN 02539748: Linezolid Injection Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 084000068; group id 135; item number 0228; lccId None; manufacturer id EUP Source form: Inj-300mL Pk; strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $88.7400; ministry $88.7400 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02539748 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102848
Interchangeable products
Linezolid Injection · DIN 02481278 · $88.7400 Zyvoxam · DIN 02243685 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02539748
Shortage record checked October 6, 2026

Zyvoxam · DIN 02243685 · 2 mg/mL · injection-300mL Pk

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Zyvoxam · DIN 02243685 Manufacturer: Pfizer Canada Inc.; listing date 2014-10-29 Health Canada: Marketed since 2006-02-07 · brand ZYVOXAM · ATC J01XX08 LINEZOLID · form Solution · route Intravenous · ingredients LINEZOLID 2 MG/ML · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Zyvoxam: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243685)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02243685). DIN 02243685: Zyvoxam Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 084000068; group id 135; item number 0228; lccId None; manufacturer id PFI Source form: Inj-300mL Pk; strength: 2mg/mL Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243685 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67615
Interchangeable products
Linezolid Injection · DIN 02481278 · $88.7400 Linezolid Injection · DIN 02539748 · $88.7400
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243685
Shortage record checked October 6, 2026

Zyvoxam · DIN 02243684 · 600 mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-31 — choose a marketed DIN from the same-category list.Discontinued July 31, 2020 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-31 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2020-07-31 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Ontario Limited Use criteria, code 362, 363, 364
Coverage limit: For the treatment of patients with: Reason for Use code 362 Methicillin-resistant Staphylococcus species (MRSA, MRSE) infections* in patients who are intolerant or have failed vancomycin therapy, or have contraindications to venous access. Coverage limit: LU Authorization Period: 1 year Reason for Use code 363 Vancomycin resistant Enterococcus species (VRE) infections* in patients switching from IV linezolid. Coverage limit: LU Authorization Period: 1 year Reason for Use code 364 Step-down therapy for the treatment of methicillin-resistant Staphylococcus species or vancomycin resistant Enterococcus species (VRE) infections* after parenteral therapy or hospital/ emergency department discharge. Coverage limit: * Infections must be documented and culture proven. Not approved for colonization (e.g. nares, urine, etc). Maximum 28 days supply. Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Zyvoxam · DIN 02243684 Manufacturer: Pfizer Canada Inc.; listing date 2003-01-30 Health Canada: Cancelled post market since 2020-07-31 · brand ZYVOXAM 600 MG · ATC J01XX08 LINEZOLID · form Tablet · route Oral · ingredients LINEZOLID 600 MG · company Pfizer canada ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Zyvoxam: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243684)

Source record
DIN 02243684: Zyvoxam Raw flags: notABenefit=Y, sec3=Y Item: 084000054; group id 136; item number 0229; lccId 00014; manufacturer id PFI Source form: Tab; strength: 600mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243684 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67614
Interchangeable products
Apo-Linezolid · DIN 02426552 · $19.3041 Jamp Linezolid · DIN 02520354 · $19.3041 Sandoz Linezolid · DIN 02422689 · $19.3041
Shortage status: discontinued (July 31, 2020, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243684
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 31, 2020 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS ZYVOXAM (linezolid injection and powder for oral suspension) is indicated for: Treatment of adult patients with the following infections, when caused by susceptible strains of the designated aerobic Gram-positive micro-organisms: Note: ZYVOXAM is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see 7 WARNINGS AND PRECAUTIONS). Vancomycin-Resistant Enterococcus faecium (VREF) Infections: ZYVOXAM is indicated for the treatment of the following infections when due to VREF: • Intra-abdominal, skin and skin-structure, and urinary tract infections (including cases associated with concurrent bacteremia) (see 14 CLINICAL TRIALS). Note: This indication for VREF is based on non-comparative studies. Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). Community-acquired pneumonia caused by Streptococcus pneumoniae (penici… https://pdf.hres.ca/dpd_pm/00074542.PDF PM date: APR 02, 2001 Source product: ZYVOXAM; DIN 02243685; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Zyvoxam · DIN 02243684 Shortage status: discontinued (2020-07-31, reported by PFIZER CANADA ULC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243684

Check this DIN again

Other review policies

For Linezolid Injection, Zyvoxam: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026